 |
|
Use of Warfarin for Nonvalvular Atrial Fibrillation in Nursing Home Patients
Thomas E. Lackner, PharmD;
George N. Battis, MD
Arch Fam Med. 1995;4(12):1017-1026.
References
Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.
| |
1. National Center for Health Statistics. Advanced report of final mortality statistics, 1988. Monthly Vital Stat Report. 1990;39(suppl_7):21.
2. National Center for Health Statistics. 1985 National Nursing Home Survey. Vital Health Stat 13. 1985;No. 102. 3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
FREE FULL TEXT
4. Petersen P, Boysen G, Godtfredsen J, Andersen ED. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1:175-179.
PUBMED
5. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1511.
ABSTRACT
6. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84:527-539.
FREE FULL TEXT
7. Connoly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18:349-355.
ABSTRACT
8. Ezekowitz MD, Bridgers SL, James KE, et al. VA cooperative study of warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327:1406-1412.
ABSTRACT
9. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-691.
PUBMED
10. European Atrial Fibrillation Trial Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262.
PUBMED
11. Hirsh J, Dalen JE, Deykin D, Poller L. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1992;102(suppl 4):312S-326S.
PUBMED
12. Poller L. Progress in standardization in anticoagulant control. Hematol Rev. 1987;1:225-241.
13. Hirsh J, Poller L. The International Normalized Ratio: a guide to understanding and correcting its problems. Arch Intern Med. 1994;154:282-288.
FREE FULL TEXT
14. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993;95:315-328.
PUBMED
15. Levine MN, Hirsh J, Landefeld S, Raskob G. Hemorrhagic complications of anticoagulant treatment. Chest. 1992;102(suppl):352S-363S.
PUBMED
16. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, I: clinical features of patients at risk. Ann Intern Med. 1992;116:1-5.
FREE FULL TEXT
17. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, II: echocardiographic features of patients at risk. Ann Intern Med. 1992;116:6-12.
FREE FULL TEXT
18. Hansten PD, Horn JR, eds. Drug Interactions: A Clinical Perspective and Analysis of Current Developments. Vancouver, Wash: Applied Therapeutics Inc; 1991. 19. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med. 1982;306:1018-1022.
ABSTRACT
20. Phillips SJ, Whisnant JP, O'Fallon WM, Frye RL. Prevalence of cardiovascular disease and diabetes mellitus in patients of Rochester, Minnesota. Mayo Clin Proc. 1990;65:344-359.
PUBMED
21. Kutner M, Nixon G, Silverstone F. Physicians attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med. 1991;151:1950-1953.
FREE FULL TEXT
22. McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett ELC. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med. 1995;155:277-281.
FREE FULL TEXT
23. The Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-1457.
FREE FULL TEXT
24. Hirsh J, Dalen JE, Fuster V, Harker LB, Salzman EW. Aspirin and other platelet-active drugs: the relationship between dose, effectiveness, and side effects. Chest. 1992;102(suppl 4):327S-336S.
PUBMED
25. Stroke Prevention in Atrial Fibrillation Study Group Investigators. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med. 1990;322:863-868.
ABSTRACT
26. Fisher CM. Reducing risks of cerebral embolism. Geriatrics. 1979;34:59-66.
PUBMED
27. Lipsitz LA, Jonsson PV, Kelley MM, Koestner JS. Causes and correlates of recurrent falls in ambulatory frail elderly. J Gerontol. 1991;46:M114-M122.
ABSTRACT
28. Guyatt GH, Sackett DL, Cook DJ. Users' guide to the medical literature: how to use an article about therapy or prevention: what are the results and will they help me in caring for my patients? JAMA. 1994;271:59-63.
FREE FULL TEXT
29. Ezekowitz MD, James KE. Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:1508-1509.
PUBMED
30. Gurwitz JH, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med. 1992;11:901-904.
31. Portable prothrombin time monitor. Med Lett Drugs Ther. 1995;37:24.
PUBMED
|
